Tests RAS(ON) inhibitors in lung cancer with RAS gene mutations
Tests new RAS(ON) inhibitor drugs in adults with advanced RAS-mutated lung cancer.
Plain-language title generated from the registry record
Registry title: Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Key facts
- Where
- Berlin, Cologne, Dresden, Frankfurt Am Main, and Heidelberg, GermanySee the 5 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced lung cancer (NSCLC) caused by a RAS gene change. It tests new RAS(ON) inhibitor drugs, alone or with standard treatment.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Locally advanced or metastatic cancer that cannot be cured by surgery. Subprotocol A: KRAS G12C-mutated solid tumor. Subprotocol B: RAS-mutated NSCLC. Subprotocols C and D: RAS G12D-mutated NSCLC.
- Earlier treatment
- People must have had standard therapy that fits their tumor type and stage.
- Biomarker or test result
- A documented RAS gene change: KRAS G12C (Subprotocol A), RAS mutation (Subprotocol B) or RAS G12D (Subprotocols C and D).
Main reasons for not taking part
- Primary tumors of the brain or spinal cord (central nervous system)
- Stomach or bowel problems that could change how the drugs are absorbed
- Major surgery less than 28 days before the first dose
- Current or past interstitial lung disease or pneumonitis that needed steroids
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which best describes your lung cancer?
- Has the cancer spread to other parts of the body, or is it too advanced to be removed by surgery?
Source: NCT06162221, who can take part
Where in Germany
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
- University Hospital Cologne AöRCologne, GermanyTaking people
- Technische Universitaet DresdenDresden, GermanyTaking people
- Goethe University FrankfurtFrankfurt Am Main, GermanyTaking people
- Thoraxklinik Heidelberg gGmbHHeidelberg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Revolution Medicines, Inc.
- Trial code
- NCT06162221EU 2025-521147-21-00
- Record updated
- 19 October 2026
- Original description
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other.Read full original descriptionShow less
A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other.
The first four subprotocols include the following:
Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805
Inclusion: All Patients (unless otherwise noted):; ≥ 18 years of age; ECOG PS is 0 to 1; Adequate organ function as outlined by the study; Received prior standard therapy appropriate for tumor type and stage; Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A); Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B); Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D).
Exclusion: Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs; Major surgery < 28 days of first dose; Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids; Other inclusion/exclusion criteria may apply; All Patients:; Primary central nervous system (CNS) tumors.